KCM
LGND icon

Kennedy Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Kennedy Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
+33,353
New +$7.86M 0.19% 185
2024
Q1 		– Sell
-33,853
Closed -$2.42M – 753
2023
Q4 		$2.42M Sell
33,853
-1,846
-5% -$109K 0.05% 452
2023
Q3 		$2.14M Buy
35,699
+1,215
+4% +$80K 0.05% 447
2023
Q2 		$2.49M Buy
34,484
+19,815
+135% +$1.49M 0.06% 419
2023
Q1 		$1.08M Buy
14,669
+3,422
+30% +$243K 0.03% 478
2022
Q4 		$751K Sell
11,247
-6,803
-38% -$442K 0.02% 518
2022
Q3 		$970K Buy
18,050
+2
+0% +$118 0.03% 485
2022
Q2 		$1M Buy
18,048
+880
+5% +$49.9K 0.03% 473
2022
Q1 		$1.21M Sell
17,168
-168
-1% -$12.2K 0.03% 479
2021
Q4 		$1.67M Sell
17,336
-605
-3% -$55.9K 0.04% 468
2021
Q3 		$1.56M Sell
17,941
-1,074
-6% -$83.1K 0.03% 486
2021
Q2 		$1.56M Sell
19,015
-4,945
-21% -$411K 0.03% 499
2021
Q1 		$2.28M Sell
23,960
-152,517
-86% -$14.4M 0.05% 503
2020
Q4 		$10.9M Buy
176,477
+85,431
+94% +$4.87M 0.25% 126
2020
Q3 		$5.41M Sell
91,046
-158,313
-63% -$10.8M 0.16% 244
2020
Q2 		$17.4M Sell
249,359
-11,659
-4% -$739K 0.5% 19
2020
Q1 		$11.8M Buy
261,018
+148,625
+132% +$8.42M 0.44% 22
2019
Q4 		$7.31M Buy
112,393
+20,578
+22% +$1.38M 0.18% 199
2019
Q3 		$5.7M Buy
91,815
+65,795
+253% +$4.13M 0.14% 275
2019
Q2 		$1.85M Sell
26,020
-48,164
-65% -$3.55M 0.04% 547
2019
Q1 		$5.82M Buy
74,184
+55,875
+305% +$4.23M 0.14% 282
2018
Q4 		$1.55M Sell
18,309
-57,798
-76% -$6.16M 0.04% 564
2018
Q3 		$13M Buy
76,107
+1,468
+2% +$221K 0.24% 111
2018
Q2 		$9.65M Buy
74,639
+1,638
+2% +$183K 0.18% 174
2018
Q1 		$7.52M Sell
73,001
-1,290
-2% -$128K 0.15% 244
2017
Q4 		$6.35M Sell
74,291
-341
-0.5% -$29.6K 0.11% 329
2017
Q3 		$6.34M Buy
+74,632
New +$5.91M 0.11% 317

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management's LGND Position: Q2 2026 in Review

Kennedy Capital Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 33,353 shares worth $10.5M. The stake represents 0.19% of the portfolio and ranks #185 among its holdings. This is a return to the name: Kennedy Capital Management previously reported a position in LGND as recently as Q4 2023.

Kennedy Capital Management first reported a position in LGND in Q3 2017 and has held it in 27 quarters since. The position peaked at $17.4M in Q2 2020. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Kennedy Capital Management held 33,353 shares of Ligand Pharmaceuticals worth $10.5M as of Q2 2026.
  • Ligand Pharmaceuticals was a new Kennedy Capital Management position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.19% of Kennedy Capital Management's portfolio in Q2 2026, its #185 holding.
  • Kennedy Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2017 and has held it in 27 quarters since.
  • Kennedy Capital Management's Ligand Pharmaceuticals position peaked at $17.4M in Q2 2020.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.